Immune to Cancer: The CRI Blog
-
ASCO19 Recap: Caring for Every Patient, Learning from Every Patient
ASCO19 highlighted a number of immunotherapy developments, including those relating to long-term survival, introducing immunotherapy earlier, biomarkers,…
-
ASCO19 Day 5 Update: CAR T Cells for Pleural Cancers and More Melanoma News
The final day of ASCO19 covered CAR T cells for pleural cancers and long-term updates on several…
-
ASCO19 Day 4 Update: Kidney Cancer, Liver Cancer, Stomach Cancer, Esophageal Cancer, and Melanoma
The fourth day at ASCO19 highlighted immunotherapy strategies for patients with kidney cancer, liver cancer, stomach cancer,…
-
ASCO19 Day 3 Update: Immunotherapy for Brain Cancer, Ovarian Cancer, Lung Cancer, and Patients with HIV
The third day at ASCO19 highlighted immunotherapy strategies for patients with brain cancer, ovarian cancer, lung cancer,…
-
ASCO19 Day 2 Update: Biomarkers in Checkpoint Immunotherapy, Targeting Macrophages, and Cellular Immunotherapies
The second day at ASCO19 highlighted biomarkers that may have value in the context of PD-1 checkpoint…
-
ASCO19 Day 1 Update: Lung Cancer, Head and Neck Cancer, and the Cost of Immunotherapy
The opening day at ASCO19 discussed various immunotherapy combinations for head and neck cancer, a bispecific antibody…
-
Connecting and learning about immunotherapy in San Francisco
On June 30, 2018, over 200 patients, caregivers, and advocates gathered to connect with experts and learn…
-
30 Days of CRI Impact: How Bacteria and Vaccines Can Help the Immune System Fight Cancer
This week’s breakthroughs highlight the benefits of bacteria, vaccines, and the use of immunotherapy earlier in the…
-
Bikes, Beers, and One Cause to Cure All Cancers
On June 26, 2018, 48 cyclists—CRI Associate Board members, family, and friends—biked together at SWERVE Fitness Flatiron…